Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) (vol 13, pg 1, 2021)

被引：3
|
作者：
Rebuzzi, S. E.
Signori, A.
Banna, G.
机构：
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷
关键词：
D O I：
10.1177/17588359211036552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 31 条
  • [21] Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
    Rebuzzi, S. E.
    Signori, A.
    Buti, S.
    Maruzzo, M.
    De Giorgi, U. F. F.
    Zucali, P. A.
    Procopio, G.
    Fratino, L.
    Pipitone, S.
    Mollica, V.
    Soraru, M.
    Chiellino, S.
    Lipari, H.
    Galli, L.
    Masini, C.
    Naglieri, E.
    Milella, M.
    Ricotta, R.
    Banna, G. L.
    Fornarini, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1020 - S1020
  • [22] Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
    Rebuzzi, Sara Elena
    Brunelli, Matteo
    Galuppini, Francesca
    Vellone, Valerio Gaetano
    Signori, Alessio
    Catalano, Fabio
    Damassi, Alessandra
    Gaggero, Gabriele
    Rescigno, Pasquale
    Maruzzo, Marco
    Merler, Sara
    Vignani, Francesca
    Cavo, Alessia
    Basso, Umberto
    Milella, Michele
    Panepinto, Olimpia
    Mencoboni, Manlio
    Sbaraglia, Marta
    Dei Tos, Angelo Paolo
    Murianni, Veronica
    Cremante, Malvina
    Obispo, Miguel Angel Llaja
    Maffezzoli, Michele
    Banna, Giuseppe Luigi
    Buti, Sebastiano
    Fornarini, Giuseppe
    CANCERS, 2023, 15 (08)
  • [23] The prognostic value of Meet-URO score in patients with metastatic clear cell renal cell carcinoma receiving second or third-line tyrosine kinase inhibitors/immune checkpoint inhibitors combination therapy: A real-world study
    He, Sike
    Liu, Haoyang
    Chen, Junru
    Sun, Guangxi
    Liu, Zhenhua
    Zeng, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study).
    Catalano, Fabio
    Murianni, Veronica
    Rebuzzi, Sara Elena
    Galuppini, Francesca
    Buti, Sebastiano
    Brunelli, Matteo
    Maruzzo, Marco
    Dei Tos, Angelo Paolo
    Basso, Umberto
    Banna, Giuseppe Lugi
    Signori, Alessio
    Sbaraglia, Marta
    Damassi, Alessandra
    Cremante, Malvina
    Puglisi, Silvia
    Gandini, Annalice
    Rebuzzi, Marta
    Mosca, Alessandra
    Fornarini, Giuseppe
    Rescigno, Pasquale
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [25] Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)
    Verzoni, E.
    Procopio, G.
    Bottiglieri, A.
    Stellato, M.
    Rametta, A.
    Zucali, P. A.
    Perrucci, B.
    Fornarini, G.
    Buti, S.
    Maruzzo, M.
    Cova, A.
    Squarcina, P.
    Lalli, L.
    Mereu, A.
    Cerioli, N.
    Agnelli, L.
    Todoerti, K.
    Busico, A.
    Rivoltini, L.
    Huber, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S1022 - S1023
  • [26] Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)
    Stellato, M.
    Buti, S.
    Maruzzo, M.
    Bersanelli, M.
    Ermacora, P.
    Maiorano, B. A.
    Prati, V.
    De Giorgi, U. F. F.
    Pierantoni, F.
    Malgeri, A.
    Mennitto, A.
    Cavo, A.
    Vitale, M. G.
    Santoni, M.
    Carella, C.
    Procopio, G.
    Verzoni, E.
    Santini, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1214 - S1215
  • [27] Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi-institute study
    Ito, Toshiki
    Mizutani, Kosuke
    Takahara, Kiyoshi
    Ando, Ryosuke
    Yasui, Takahiro
    Shiroki, Ryoichi
    Koie, Takuya
    Miyake, Hideaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (01)
  • [28] A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-URO 8 study).
    Verzoni, Elena
    Huber, Veronica
    Cova, Agata
    Squarcina, Paola
    Frati, Paola
    Lalli, Luca
    Stroscia, Martina
    Bottiglieri, Achille
    Fotia, Giuseppe
    Sepe, Pierangela
    Stellato, Marco
    Zucali, Paolo Andrea
    Perrucci, Bruno
    Buti, Sebastiano
    Maruzzo, Marco
    Vittimberga, Isabella
    Fornarini, Giuseppe
    Rivoltini, Licia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC) (vol 3, pg 256, 2021)
    Marchioni, Michele
    Kriegmair, Maximilian
    Heck, Mathias
    Amiel, Thomas
    Porpiglia, Francesco
    Checcucci, Enrico
    Campi, Riccardo
    Minervini, Andrea
    Mari, Andrea
    Van Bruwaene, Siska
    Linares, Estefania
    Hevia, Vital
    Musquera, Mireia
    D'Anna, Mauricio
    Derweesh, Ithaar
    Bradshaw, Aaron
    Autorino, Riccardo
    Guruli, Georgi
    Veccia, Alessandro
    Roussel, Eduard
    Albersen, Maarten
    Pavan, Nicola
    Claps, Francesco
    Antonelli, Alessandro
    Palumbo, Carlotta
    Klatte, Tobias
    Erdem, Selcuk
    Mir, Maria Carmen
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 517 - 517
  • [30] Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)
    Motzer, R. J.
    Escudier, B.
    Bukowski, R.
    Rini, B. I.
    Hutson, T. E.
    Barrios, C. H.
    Lin, X.
    Fly, K.
    Matczak, E.
    Gore, M. E.
    BJU INTERNATIONAL, 2012, 109 : 8 - 8
1234